Medway Metabonomics Group, University of Greenwich, Chatham Maritime, Kent ME4 4TB, UK.
Prog Nucl Magn Reson Spectrosc. 2017 Nov;102-103:1-14. doi: 10.1016/j.pnmrs.2017.04.003. Epub 2017 May 6.
Metabolic profiling by NMR spectroscopy or hyphenated mass spectrometry, known as metabonomics or metabolomics, is an important tool for systems-based approaches in biology and medicine. The experiments are typically done in a diagnostic fashion where changes in metabolite profiles are interpreted as a consequence of an intervention or event; be that a change in diet, the administration of a drug, physical exertion or the onset of a disease. By contrast, pharmacometabonomics takes a prognostic approach to metabolic profiling, in order to predict the effects of drug dosing before it occurs. Differences in pre-dose metabolite profiles between groups of subjects are used to predict post-dose differences in response to drug administration. Thus the paradigm is inverted and pharmacometabonomics is the metabolic equivalent of pharmacogenomics. Although the field is still in its infancy, it is expected that pharmacometabonomics, alongside pharmacogenomics, will assist with the delivery of personalised or precision medicine to patients, which is a critical goal of 21st century healthcare.
通过 NMR 光谱或连接质谱进行代谢物轮廓分析，即代谢组学，是生物学和医学中基于系统的方法的重要工具。这些实验通常以诊断方式进行，其中代谢物谱的变化被解释为干预或事件的结果；无论是饮食的改变、药物的给药、体力活动还是疾病的发作。相比之下，药物代谢组学采用预测代谢物轮廓的方法，以便在药物给药之前预测药物剂量的影响。通过比较给药前不同组别的代谢物轮廓差异，可以预测药物给药后的反应差异。因此，范式发生了转变，药物代谢组学是药物基因组学的代谢等效物。尽管该领域仍处于起步阶段，但预计药物代谢组学将与药物基因组学一起，帮助为患者提供个性化或精准医疗，这是 21 世纪医疗保健的关键目标。
